Kornimate/medical-research-clean huggingface dataset:
neurogenic bladder and quality of life in patients with stroke

Conditions: Stroke, Complication; Neurogenic Bladder

Summary: this study investigated effects of the neurogenic bladder on the quality of life in stroke survivors. patients were divided into two groups: the first group consisted of patients with neurogenic bladder and the second group consisted of patients without neurogenic bladder.

neurogenic bladder after stroke is a commonly encountered medical condition which slows down the recovery process and exacerbates the functional status of the patient. the neurogenic bladder may possibly affect the quality of life of patients with stroke. objectives: the aim of this study is to investigate the relationship between the quality of life and the neurogenic bladder in turkish stroke survivors. methods: 71 patients with stroke were included in the study. patients were divided into two groups: the first group consisted of patients with neurogenic bladder and the second group consisted of patients without neurogenic bladder. short form-36 (sf-36), barthel index (bi), functional ambulation category (fac), mini-mental test (mmt) and beck depression inventory (bdi) questionnaires were applied to both groups for clinical evaluations.

Eligibility criteria:
inclusion criteria: * hemorrhagic or ischemic stroke * no previous stroke history * disease duration \> 6 months exclusion criteria: * patients with different stroke etiologies other than cerebrovascular events (such as traumatic and tumoral pathologies) * previous multiple stroke history * pre-stroke urinary complaints * previous urogenital surgery history * spinal cord injury (sci) * prostate volume of \> 35ml documented with urinary ultrasonography * bladder outlet obstruction * poorly controlled diabetes mellitus (dm) * concomitant neurological diseases such as multiple sclerosis and parkinson's disease * anticholinergic, alpha agonist-antagonist drug use * sensory and global aphasia * severe communication impairment

Keywords: urinary bladder, neurogenic quality of life socioeconomic factors stroke rehabilitation
ultrathin versus conventional esophagogastroduodenoscopy in unsedated patient with or without local pharyngeal anaesthesia

Conditions: Dyspepsia

Summary: the purpose of this study is to investigate whether an ultrathin endoscope will improve a patient's tolerance during the procedure. in addition, this study will look at whether local pharyngeal anaesthesia is necessary during ultrathin endoscopy.


Eligibility criteria:
inclusion criteria: * aged between 18-70 exclusion criteria: * previous experience of upper endoscopy * allergy to local pharyngeal anaesthesia * patient requesting sedation during endoscopy

Keywords: upper endoscopy local pharyngeal anaesthesia ultrathin endoscope
evaluation of the necessity of long-term pharmacological treatment with antipsychotics in schizophrenic patients

Conditions: Schizophrenia; Schizophrenia and Disorders With Psychotic Features; Schizoaffective Disorders

Summary: the main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. relapse is defined as primary outcome.

the main objective of the trial is to evaluate for the first time, how long an antipsychotic relapse-prevention should be continued and to which time a patient is protected enough, so that a guided withdrawal or reduction of the medication seems appropriate. relapse is defined as primary outcome. we include patients with schizophrenia or schizoaffective disorder in remission for at least 3 years under a stable antipsychotic medication.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder * the participants have to be in remission for at least 3 years (i.e. no psychiatric hospitalisation) under a stable antipsychotic medication. remission will be measured using the remission criteria by andreasen et al. (2005) score ≤3 for the items concerning psychosis of the "positive and negative syndrom scale" (panss; kay et al., 1987): "delusions" (p1), "conceptual disorganisation" (p2), "halluzinations" (p3), "mannerisms and posturing" (g5) and "unusual thought content" (g9) and a score ≤3 on the "clinical global impression severity scale" (cgi-s; guy, 1976) * able to give informed consent exclusion criteria: * actively suicidal * serious medical illnesses * known non-complience concerning the medication * medication with clozapin * medication with antidepressants and mood stabilisors that were initiated during the last 6 weeks before study enrollment * patients with substance dependence other than nicotine or caffeine within 6 months prior to baseline * unability to give informed consent * pregnancy
integrated biomarker and imaging study - 2

Conditions: Atherosclerosis

Summary: ibis-2 is a study using sb-480848 versus placebo in subjects with angiographically documented coronary heart disease. endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.

integrated biomarker and imaging study -2 (ibis-2): an international, multicenter, randomized, placebo-controlled, parallel-group, 1 year treatment, integrated biomarkers and imaging study in subjects with angiographically documented coronary heart disease (chd) to examine the effects of the novel lipoprotein-associated phospholipase a2 (lp-pla2) inhibitor sb-480848 on intermediate cardiovascular endpoints, patient safety and tolerability.

Eligibility criteria:
inclusion criteria: * successful pci (percutaneous coronary intervention) or uncomplicated diagnostic catheterization * suitable non-intervened coronary artery with ivus * antiplatelet therapy exclusion criteria: * clinical instability * previous cabg (coronary artery by-pass graft) surgery * planned major surgery * recent stroke * abnormal qtc * renal or hepatic impairment * uncontrolled hypertension * use of corticosteroids * class iii or iv heart failure * asthma

Keywords: coronary artery disease lipoprotein-associated phospholipase a2 palpography hs-crp endothelial function intravascular ultrasound
study of nasal mucosa histopathological changes in chronic hypersensitivity pneumonitis

Conditions: Hypersensitivity Pneumonitis; Nasal Mucosal Disorder

Summary: background:hypersensitivity pneumonitis (hp) is an interstitial lung disease that develops after inhalation of organic or inorganic antigens in susceptible individuals. the nasal mucosa is constantly exposed to these antigens that can irritate the respiratory mucosa. objectives: to assess the burden of sinonasal symptoms in hp patients and to evaluate the nasal histopathology in those patients.


Eligibility criteria:
inclusion criteria: * all patients with clinical and radiological features of hp exclusion criteria: * respiratory failure * patients on anticoagulants

Keywords: hypersensitivity pneumonitis nasal mucosa histopaholgical changes
mindfulness-based therapy for serious mental illness

Conditions: Serious Mental Illness; Schizophrenia; Major Depressive Disorder; Bipolar Disorder

Summary: serious mental illness (smi), encompassing schizophrenia-spectrum and major mood disorders, has been estimated to affect approximately 5.4% of the u.s. adult population each year. research shows low rates of evidence-based treatment being provided to patients with smi. this is unfortunate, because evidence-based psychological therapies have been shown to be effective for improving outcomes in smi. one such efficacious psychological intervention is mindfulness-based therapy (mbt), which integrates mindfulness practice with cognitive-behavioral strategies to improve illness management. previous trials conducted in the united kingdom have shown that mbt improves symptoms and functioning in community-based outpatients with smi, including in routine practice settings. in the u.s., most patients with smi receive treatment at local community mental health centers (cmhcs). however, patients in cmhcs often cannot access evidence-based therapies like mbt due to the lack of trained staff able to provide these interventions. further, previous studies of mbt have been conducted exclusively outside the u.s. it is essential to confirm that mbt is effective when delivered for patients with smi in the u.s., and how it can be sustainably implemented in cmhcs where this clinical population is commonly treated. thus, the investigators propose to test the effectiveness of mbt for smi and study its implementation in a typical cmhc setting. the investigators will randomize 160 patients with smi (psychotic-spectrum and major mood disorders) to receive treatment as usual (tau) vs tau plus mbt delivered by frontline clinicians in a large, diverse cmhc. the investigators will conduct blinded assessments at baseline and at 6- (mid), 12- (post), and 24-weeks (follow-up). consistent with an experimental therapeutics approach, the investigators will examine potential mechanisms of action (e.g., mindfulness skills), as well as collect implementation-focused quantitative and qualitative data from our community partners (patients, administrators, clinicians). if found to be effective and aided by a certified training program and the implementation data collected, mbt could be adopted as a future evidence-based practice and integrated into the routine community care of patients with smi, thereby reducing health disparities.


Eligibility criteria:
inclusion criteria: * currently receiving treatment in a community mental health center * diagnosed with schizophrenia-spectrum disorder or major mood disorder based on clinical interview * age 18 years or older * ability to speak and read english exclusion criteria: * not clinically stable enough to participate in treatment. * established weekly mindfulness practice
a dose-response safety study of enx-102 in patients with gad

Conditions: General Anxiety Disorder

Summary: this is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of enx-102 and determine a dose-response for the effects of enx-102 in patients with gad


Eligibility criteria:
key inclusion criteria: * male or female, inclusive of any gender identity, aged 18 to 65 years, inclusive * diagnosed with gad according to the dsm-v, confirmed by mini * experiencing clinically significant generalized anxiety as measured by ham-a score ≥18 and at least moderately severe core symptoms of anxious mood and tension as measured by ham-a items 1 and 2, respectively, with scores each ≥2 key exclusion criteria: * clinically predominant psychiatric diagnosis other than gad per the mini * any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or current posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder * ingested prohibited medication within 5 half-lives prior to day 1 * current or recent moderate or severe substance use disorder as assessed by the mini * unwilling or unable to abstain from alcohol or other recreational psychoactive substances such as marijuana during participation in the trial * has significant progressive disorders or unstable medical conditions * is unable to comply with the requirements of the study or, in the opinion of the investigator, is unsuitable for the study

Keywords: anxiety
a study evaluating the efficacy and safety of afimetoran compared with placebo in participants with active systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of this study is to evaluate the effectiveness, safety and tolerability of afimetoran in participants with active systemic lupus erythematosus (sle). the extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with afimetoran.


Eligibility criteria:
inclusion criteria: * diagnosed ≥ 12 weeks before the screening visit and qualify as having sle according to the sle international collaborating clinics (slicc) classification criteria at the screening visit * test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody ≥ 1:80, anti-double-stranded deoxyribonucleic acid (dsdna) antibody, or anti-smith antibody. * have a total hybrid systemic lupus erythematosus disease activity index (sledai) score ≥ 6 points and clinical hybrid sledai score ≥ 4 points with joint involvement and/or rash exclusion criteria: * active severe lupus nephritis (ln) as assessed by the investigator * active or unstable neuropsychiatric lupus manifestations defined by the hybrid sledai * diagnosis of mixed connective tissue disease for which the predominant diagnosis is not sle * antiphospholipid syndrome other protocol-defined inclusion/exclusion criteria apply

Keywords: bms-986256 systemic lupus erythematosus sle connective tissue diseases autoimmune diseases immune system diseases afimetoran
prognostic model of gc/tac in the treatment of mn

Conditions: Idiopathic Membranous Nephropathy

Summary: the goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (imn) under the treatment of glucocorticoid + tacrolimus. the main questions it aims to answer are: * to explore the factors that can predict the prognosis difference in patients with imn under the treatment of glucocorticoid + tacrolimus * to establish a clinical prediction model and verify it to provide a reference for the early participants will receive standard the treatment of glucocorticoid + tacrolimus treatment and will then be divided into remission and non remission groups based on the treatment effect after the standard treatment cycle. blood, urine, and fecal samples were collected from patients to explore possible factors influencing treatment efficacy. researchers will compare \[remission group and non-remission group\] to see if the gut microbiota and its metabolites are factors that influence the efficacy of treatment.


Eligibility criteria:
inclusion criteria: 1. aged 18-75 years, the patient was diagnosed as idiopathic membranous nephropathy or anti phospholipase a2 receptor (pla2r) antibody positive by renal puncture biopsy, and the clinical data were complete; 2. according to the kidney disease: improving global outcomes (kdigo) guidelines in 2020, it conforms to the medium and high risks in the risk level of progression of renal function loss. 3. in general, they are in good condition, have a good understanding of their own conditions and physical conditions, have self-awareness, and can communicate well with others; 4. volunteer to participate in the study, understand the significance of this experiment and the indicators to be measured, and sign the informed consent form. exclusion criteria: 1. there are factors causing secondary membranous nephropathy, such as immune diseases (systemic lupus erythematosus), tumors/infections (viral hepatitis), drugs or toxins; 2. at the same time, immunoglobulin a nephropathy (igan), interstitial nephritis, acute nephritis and other renal pathological types were combined; 3. the medication was not standardized during the treatment process, accompanied by serious infection, acute renal injury and other complications, and serious cardiovascular, cerebrovascular, digestive and blood system diseases; 4. during follow-up, the patient cannot actively cooperate or accurately understand and express.
efficacy and safety of renal denervation on isolated diastolic hypertension

Conditions: Hypertension; Renal Denervation Therapy

Summary: this study aims to evaluate the efficacy and safety of renal denervation (rdn) in patients with isolated diastolic hypertension (idh). the randomized, sham-controlled, multicenter clinical trial will recruit 44 participants (33 in the treatment group and 11 in the sham control group) to assess changes in blood pressure and adverse events over a 6-month follow-up period. the study is expected to provide new evidence for the use of rdn as a treatment for idh.


Eligibility criteria:
inclusion criteria: - 1. age 18-45 years. 2. diagnosed with isolated diastolic hypertension (office sbp \< 140 mmhg and dbp ≥ 90 mmhg without antihypertensive medication). 3. signed informed consent. exclusion criteria: * 1. office dbp ≥ 110 mmhg. 2. secondary hypertension or arrhythmias affecting blood pressure accuracy (e.g., atrial fibrillation). 3. comorbidities such as diabetes, chronic kidney disease (egfr \< 30 ml/min/1.73m²), coronary artery disease, or heart failure. 4. history of stroke or myocardial infarction. 5. known bleeding disorders or inability to tolerate anticoagulation. 6. renal artery abnormalities or prior renal artery/coronary artery interventions. 7. pregnancy, breastfeeding, or planning to become pregnant. 8. life expectancy \< 1 year. 9. participation in another clinical trial.
laser and therapeutic ultrasound in the management of the chronic non-specific low back pain

Conditions: Chronic Low Back Pain

Summary: the objective of this study is evaluate the laser and ultrasound effect on pain and disability in women with non-specific chronic low back pain.


Eligibility criteria:
inclusion criteria: * non-specific chronic low back pain * moderate pain * eutrophics women exclusion criteria: * disk herniation * cardiac diseases * psychiatrics diseases * endocrinous diseases * fractures of the spine * fractures of lower members * diabetics * dental emergency * local infections * local non sensibility * analgesics and anti-inflammatories in use * neurologic diseases * pregnancy

Keywords: chronic non-specific low back pain clinical trial disability women
ddi study to investigate the impact of itraconazole on the pharmacokinetics of dorzagliatin

Conditions: Drug Interaction

Summary: the purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of dorzagliatin.


Eligibility criteria:
inclusion criteria: * age 30-65 * body weight ≥ 50 kg * bmi ≥ 19.0 kg/m2 and ≤ 30.0 kg/m2 * hba1c ≥ 7% and ≤ 10.5% * fpg ≥ 7.5 mmol/l and ≤ 13.3 mmol/l exclusion criteria: * t1dm * use of prescription or otc medications, and herbal within 14 days prior to dosing * blood donation * any surgery or treatment that may impact the adme of the drug
east asian breast cancer genome atlas and recurrence risk prediction

Conditions: Breast Cancer

Summary: this project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for east asian breast cancer patients. the study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. aims to identify unique genetic alterations in asian tumors, to identify the susceptible genes for breast carcinogenesis in east asia, and to establish the new platform for accurate prediction of recurrence. the investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of east asian breast tumors.


Eligibility criteria:
inclusion criteria: * 1. aged more than 20-year-old at the time of informed consent. * 2. an unconfirmed breast tumor, or have histologically confirmed invasive breast cancer. * 3. have radiological or objective evidence of breast tumor size ≥1 cm. * 4. be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue. * 5. be able to sign an informed consent. exclusion criteria: * 1. have histologically confirmed ductal carcinoma in situ (dcis). * 2. stage i, ii or iii breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy. * 3. stage iv or metastatic breast cancer patients who have received chemotherapy.
comparison of short term outcomes between totally laparoscopic and laparoscopy-assisted distal gastrectomy with billroth-ii reconstruction and d2 lymphadenectomy for locally advanced gastric cancer

Conditions: Total Laparoscopic Distal Gastrectomy; Locally Advanced Gastric Cancer

Summary: prospective randomized controlled multicenter clinical trial for comparison of safety between totally laparoscopic distal gastrectomy(tldg) and laparoscopy-assisted distal gastrectomy(ladg) with billroth-ii reconstruction and d2 lymphadenectomy for locally advanced gastric cancer


Eligibility criteria:
inclusion criteria: * the diagnosis of gastric cancer was confirmed by pathological examination * preoperative staging as ct2-4an0-3m0 according to ajcc-7th * no accompany with another cancer * ecog 0-1 * asa i-iii * agreement exclusion criteria: * pregnant or suckling period * patients with a history of preoperative chemoradiotherapy * patients with unable to finish d2 lymphadenectomy or r0 resection * laparoscopic surgery contraindications * serious organ disfunction * accompany with serious mental disease * continuous treatment with steroid in 1 month * disagreement
efficacy of twice daily application of leo 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata.

Conditions: Alopecia Areata

Summary: this clinical trial attempts to investigate the efficacy of leo 124249 ointment in the treatment of alopecia areata on the eyebrows.


Eligibility criteria:
inclusion criteria: * clinical unequivocal diagnosis of alopecia areata (patchy, univeralis and totalis), on both scalp and eyebrows as assessed by the investigator. * maximal disease duration of current episode of alopecia areata on the eyebrows of 3 years at screening. * maximal alopecia areata disease duration - defined as years of active disease - in other locations than eyebrows of 10 years at screening. exclusion criteria: * clinical diagnosis of diffuse type alopecia areata as assessed by the investigator. * any topical, intralesional therapy or procedure applied within 2 cm of the treatment area, within 4 weeks of randomisation, which in the opinion of the investigator, could interfere with the trial assessments. this includes, but is not limited to: corticosteroids, calcineurin inhibitors, calcipotriol, minoxidil, antimicrobials, prostaglandin analogs (e.g. bimatoprost), herbal extracts, topical immunotherapy with allergens or irritants and any laser or phototherapy, and eyebrow tattoo. * any systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids (including intralesional treatment outside the trial treatment area), or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 4 weeks prior to randomisation. * any biologic medicinal product targeting the immune system within 5 half-lives and minimum 4 weeks prior to randomisation (e.g. anti-tnfα, anti-il17, anti il12/23, anti il-4rα targeting drugs). * systemic jak inhibitor ruxolitinib (jakafi®/jakavi®), tofacitinib (xeljanz®) at any time prior to randomisation.